GlassScriptPhysician profile
Mari Adachi
NPI 1104928340
$3,404.17
in general payments reported to CMS, 2019-2025
23 companies · $1,793 in 2025
The $1,793 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2021: $15.65 · 2022: $81.20 · 2023: $278 · 2024: $898 · 2025: $1,793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,639 · Education: $331.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,638.79 |
| Education | $331.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $418.65 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Harmony Biosciences LLC | $377.52 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $314.76 | 2024-2025 | |
| Genzyme Corporation | $312.83 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $286.35 | 2019-2024 | Airsupra, Breztri |
| Baxter Healthcare | $215.24 | 2023-2025 | Hillrom - Vest System Model 105 Home Care |
| Zoll Respicardia, INC. | $188.23 | 2019-2025 | Remede System |
| Inspire Medical Systems, INC. | $172.86 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.61 | 2024-2025 | Ofev, Jascayd |
| Viatris Specialty LLC | $171.81 | 2025 | Yupelri |
| Medtronic USA, INC. | $160.63 | 2019 | |
| Resmed Corp | $104.60 | 2023-2024 | |
| Mylan Specialty L.P. | $89.45 | 2022-2024 | Yupelri |
| Electromed, INC. | $73.26 | 2024-2025 | Smartvest |
| Amgen INC. | $70.59 | 2025 | Tezspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $69.10 | 2025 | Zepbound, Mounjaro |
| Grifols USA, LLC | $51.45 | 2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $40.71 | 2025 | Ohtuvayre |
| Inogen, INC. | $29.28 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Tactile Systems Technology INC | $27.27 | 2024 | Flexitouch Plus, Entre Plus |
| Insmed, INC. | $22.43 | 2025 | Arikayce |
| Philips North America LLC | $18.43 | 2024 | (7999) Src Undivided |
| Mallinckrodt Hospital Products INC. | $16.11 | 2025 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Adachi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.